ArticleNature medicine2019
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
Abstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 193 citations in OpenAlex.
- A comprehensive overview of the molecular features and therapeutic targets in BRAFClinical and translational medicine · 2024Pooled it
- Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Practical management of BRAF inhibitors in glioma: toxicity and resistance.CNS oncology · 2026Review
- DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.Blood advances · 2026Article
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.Cell reports. Medicine · 2026Article
- MEK interactions tune RAF kinase sensitivity to conformation-selective inhibition.Nature chemical biology · 2026Article
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.Nature communications · 2026Article
- Preclinical exploration and current clinical applications of immunotherapeutic strategies for hepatocellular carcinoma.Frontiers in immunology · 2026Review
- Article
- Computational and pharmacophore-based study of Camellia sinensis phytochemicals targeting BRAF in melanoma.Scientific reports · 2025Article
- Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.Research square · 2025Article
- Sustained Response to Pan-BRAF Inhibitor Plixorafenib (FORE8394, PLX8394) in a Young Adult With Neurodegenerative Langerhans Cell Histiocytosis.JCO precision oncology · 2025Article
- Structure-based design of potent and selective inhibitors targeting RIPK3 for eliminating on-target toxicity in vitro.Nature communications · 2025Article
- LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer.Molecular cancer · 2025Article
- BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications.International journal of molecular sciences · 2025Review
- Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies.ESMO gastrointestinal oncology · 2025Review
- Drug repurposing candidates for amyotrophic lateral sclerosis using common and rare genetic variants.Brain communications · 2025Article
- BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling.Signal transduction and targeted therapy · 2024Article
- Emerging Tumor-Agnostic Molecular Targets.Molecular cancer therapeutics · 2024Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Zhan YaoProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yijun GaoProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wenjing SuProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rona YaegerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jessica TaoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Na NaProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ying ZhangPlexxikon Inc., Berkeley, CA, USA.
Chao ZhangPlexxikon Inc., Berkeley, CA, USA.
Andrey RymarPlexxikon Inc., Berkeley, CA, USA.
Anthony TaoCenter for Neural Science, College of Arts and Sciences, New York University, New York, NY, USA.
Neilawattie M TimaulProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rory McgriskinProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nathaniel A OutmezguineProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
HuiYong ZhaoProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Qing ChangProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Besnik QeriqiProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mariano BarbacidMolecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.
Elisa de StanchinaProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David M HymanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8150-9762
Gideon BollagPlexxikon Inc., Berkeley, CA, USA.
Neal RosenProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. rosenn@mskcc.org.ORCID http://orcid.org/0000-0002-8307-654X
Memorial Sloan Kettering Cancer Center · USPlexxikon (United States)Florida State University · USSpanish National Cancer Research Centre · ES
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MInstitutional Career Development CoreKL2TR002385 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI YUAN-SHAN ZHU · 2017 to 2026
$13.3MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MStudies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3MSummer research experiences for medical students supervised by faculty mentorsR25CA020449 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Charlotte Eielson Ariyan · 1985 to 2026
$6.2MNCATS NIH HHS KL2 TR002385NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R25 CA020449NCI NIH HHS R35 CA210085NCI NIH HHS T32 CA009207NIH HHS U54 OD020355
Abstract
Activating BRAF mutants and fusions signal as RAS-independent constitutively active dimers with the exception of BRAF V600 mutant alleles which can function as active monomers
Indexed as
Protein MultimerizationSignal TransductionCell Line, TumorCell ProliferationExtracellular Signal-Regulated MAP KinasesHeterocyclic Compounds, 2-RingHumansMutationPhosphorylationProto-Oncogene Proteins B-rafSulfonamidesExtracellular Signal-Regulated MAP KinasesHeterocyclic Compounds, 2-RingPLX8394Proto-Oncogene Proteins B-rafSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.